SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL
Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO Emily Hill are named as individual defendants in a securities class action alleging Replimune's RP1 disclosures omitted unresolved FDA study-design concerns. NEW YORK, Oct. 1, 2026...